Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01708174 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
A Phase 2 study of Medulloblastoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 20
- Study locations
NCT01708174 is a Phase 2 study of Medulloblastoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 22 participants, below the 140-participant average among 29 other Medulloblastoma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT01708174, a Phase 2 study of Medulloblastoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.
Conditions Studied
Interventions
- DRUG TMZ
- DRUG LDE225
Study Locations (20)
Other
- Novartis Investigative Site - Angers
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Toulouse
- Novartis Investigative Site - Vandœuvre-lès-Nancy
- Novartis Investigative Site - Villejuif
Ontario
- Novartis Investigative Site - Toronto
- Novartis Investigative Site - Toronto
Illinois
- Ann & Robert H. Lurie Children Dept of Oncology - Chicago
Maryland
- Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Dept Onc - Baltimore
Massachusetts
- Dana Farber Cancer Institute SC-7 - Boston
New York
- Columbia University Medical Center- New York Presbyterian Dept of Oncology - New York
Ohio
- Cincinnati Children's Hospital Medical Center Division of Hema/Onco. - Cincinnati
Pennsylvania
- Children's Hospital of Pittsburgh Dept of Oncology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-05-06 |
| Est. Completion | 2016-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01708174
The ClinicalTrials.gov registry entry for NCT01708174 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 29 other Medulloblastoma trials with a reported enrollment target (84% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Medulloblastoma appearing as the primary indexed condition, and to 2 interventions - of which TMZ is the first listed.
NCT01708174 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Ontario, Illinois.
Frequently Asked Questions
What is clinical trial NCT01708174 about?
NCT01708174 is a clinical study titled "A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)". This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.
What is the current status of trial NCT01708174?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2013-05-06. Estimated completion is 2016-10-05.
What conditions does trial NCT01708174 study?
This clinical trial studies the following conditions: Medulloblastoma.
What interventions are being tested in trial NCT01708174?
The interventions under investigation include: TMZ (DRUG), LDE225 (DRUG).
Who is sponsoring clinical trial NCT01708174?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01708174 being conducted?
This trial has 20 study locations across Illinois, Maryland, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RECRUITING · Phase 2
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
RECRUITING · Phase 2
-
Digoxin Medulloblastoma Study
RECRUITING · Phase 2
-
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.